Skip to main content
CELC
NASDAQ Life Sciences

FDA Accepts sNDA for REVTORPYK in PIK3CA-Mutant Breast Cancer, PDUFA Set for June 2027

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$66.32
Mkt Cap
$3.281B
52W Low
$53.54
52W High
$151.02
52W Position info
24% above low
Off High info
56% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

CELC sits 24% above its 52-week low of $53.54.

Summary

The FDA accepted Celcuity's supplemental application for REVTORPYK in HR+/HER2- advanced breast cancer with a PIK3CA mutation, with a PDUFA goal date of June 25, 2027. This follows the sNDA submission disclosed in the August 26 8-K, which was backed by Phase 3 VIKTORIA-1 data from the PIK3CA mutant cohort. Approval would extend the label to second-line use regardless of PIK3CA status, roughly 40% of HR+/HER2- breast cancers carry that mutation, widening the addressable population beyond the July 14 approval in non-mutant patients. The drug is already commercially available but has generated no product revenue yet, and Q3 launch spending drove the net loss to $73.3 million. The June 2027 review decision is the next binary event for the stock.

At the time of this announcement, CELC was trading at $66.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $53.54 to $151.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CELC - Latest Insights

CELC
Nov 05, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.32 info
Change: +$0.280 (+0.44%) info
Market Cap: $3.16B info
CELC
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.32 info
Change: +$0.280 (+0.44%) info
Market Cap: $3.16B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $64.32 info
Change: +$0.280 (+0.44%) info
Market Cap: $3.16B info
CELC
Sep 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.00
Real-time Price: $64.32 info
Change: -$14.68 (-19%) info
Market Cap: $3.16B info
CELC
Aug 26, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $91.00
Real-time Price: $64.32 info
Change: -$26.68 (-29%) info
Market Cap: $3.16B info